摘要
目的评价尿激酶在急性心肌梗死静脉溶栓中的疗效及安全情况。方法将72例患者随机分为治疗组36例和对照组36例,在常规治疗基础上,治疗组进行尿激酶溶栓治疗,对照组给予硝酸甘油和肝素钠治疗。结果两组组间血管再通率差异有显著性(P<0.05)。结论在常规治疗基础上加用尿激酶能更有效地控制AMI,且尿激酶溶栓时间越早,再通率越高,副作用小,值得推广运用。
Objective To evaluate the clinical effects of urokinase thrombolytic therapy in the treatment of acute myocardial infarction.Methods 72 patients with AMI were randomly divided into two groups,the treatment group（36 cases） and the control group（36 cases）,on the basis of conventional therapy,the treatment group received urokinase thrombolytic therapy treatment,the control group received nitroglycerin and Heparin Sodium therapy.Results There was significant difference between the two groups＇ vessel recanalisation（P〈0.05）.Conclusion Urokinase Thrombolytic Therapy can control AMI more effectively On the basis of conventional therapy.The more early we use Urokinase,the higher recanalisation rate we can get.It has few side effects and is worth popularizing.
出处
《中外医学研究》
2011年第23期21-22,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
急性心肌梗死
尿激酶
溶栓治疗
Acute myocardial infarction
Urokinase
Thrombolytic therapy
